These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19249227)

  • 1. Second and third line treatment in non-small cell lung cancer.
    Favaretto A; Pasello G; Magro C; Schettino C; Gridelli C
    Crit Rev Oncol Hematol; 2009 Aug; 71(2):117-26. PubMed ID: 19249227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New targets for non-small-cell lung cancer therapy.
    Alvarez M; Roman E; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line treatment options in advanced non-small cell lung cancer: current status.
    Cullen M
    Semin Oncol; 2006 Feb; 33(1 Suppl 1):S3-8. PubMed ID: 16472703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
    Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
    Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
    Scagliotti GV; Selvaggi G
    Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Stage IV NSCLC. Biological treatments of lung cancer in 2008... and in the near future].
    Bergot E; Levallet G; Zalcman G
    Rev Mal Respir; 2008 Oct; 25(8 Pt 2):3S119-26. PubMed ID: 18971836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Second-line treatment and targeted therapy of advanced lung cancer].
    Nakamura Y; Yamamoto N
    Gan To Kagaku Ryoho; 2009 May; 36(5):710-6. PubMed ID: 19461168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed for the treatment of non-small-cell lung cancer.
    Manegold C; Schmid-Bindert G; Pilz LR
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Non-small cell lung cancer - from treatment of relapse to treatments for relapses].
    Souquet PJ
    Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S108-13. PubMed ID: 18235402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New targeted treatments in lung cancer--overview of clinical trials.
    Korfee S; Gauler T; Hepp R; Pöttgen C; Eberhardt W
    Lung Cancer; 2004 Aug; 45 Suppl 2():S199-208. PubMed ID: 15552800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multitargeted inhibitors in lung cancer: new clinical data.
    Bar J; Herbst RS; Onn A
    Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Stage IV NSCLC. Place of chemotherapy].
    Meert AP
    Rev Mal Respir; 2008 Oct; 25(8 Pt 2):3S107-12. PubMed ID: 18971834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach.
    Grossi F; Aita M; Defferrari C; Rosetti F; Brianti A; Fasola G; Vinante O; Pronzato P; Pappagallo G
    Oncologist; 2009 May; 14(5):497-510. PubMed ID: 19423674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line therapy for non-small-cell lung cancer.
    Arango BA; Castrellon AB; Santos ES; Raez LE
    Clin Lung Cancer; 2009 Mar; 10(2):91-8. PubMed ID: 19362951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
    Hirsch FR
    Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed in first-line treatment of non-small cell lung cancer.
    Esteban E; Casillas M; Cassinello A
    Cancer Treat Rev; 2009 Jun; 35(4):364-73. PubMed ID: 19269106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
    Burris HA
    Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics in non-small-cell lung cancer chemotherapy.
    Danesi R; Pasqualetti G; Giovannetti E; Crea F; Altavilla G; Del Tacca M; Rosell R
    Adv Drug Deliv Rev; 2009 May; 61(5):408-17. PubMed ID: 19292993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in preclinical small molecules for the treatment of NSCLC.
    Zhang Q; Feng W; Zhou H; Yan B
    Expert Opin Ther Pat; 2009 Jun; 19(6):731-51. PubMed ID: 19456275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report.
    Tiseo M; Gelsomino F; Bartolotti M; Barili MP; Ardizzoni A
    Lung Cancer; 2009 Aug; 65(2):251-3. PubMed ID: 19346026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.